5-甲酰基-2-甲基-3-糠酸甲酯 | 81661-26-9

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 呋喃
• 中文名称: 5-甲酰基-2-甲基-3-糠酸甲酯
• 英文名称: methyl 5-formyl-2-methylfuran-3-carboxylate
• 英文别名: methyl 2-methyl-5-formyl-3-furoate
• CAS: 81661-26-9
• 化学式: C₈H₈O₄
• mdl: MFCD03407372
• 分子量: 168.149
• InChiKey: WINMHOHYPKKTEM-UHFFFAOYSA-N

物化性质

• 熔点：
  83 °C

计算性质

• 辛醇/水分配系数(LogP)：
  1
• 重原子数：
  12
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.25
• 拓扑面积：
  56.5
• 氢给体数：
  0
• 氢受体数：
  4

安全信息

• 危险类别码：
  R36/37/38
• 海关编码：
  2932190090
• 安全说明：
  S24/25

SDS

Name:	Methyl 5-formyl-2-methyl-3-furoate 97% Material Safety Data Sheet
Synonym:	5-Formyl-2-methyl-furan-3-carboxylic acid methyl este
CAS:	81661-26-9

Section 1 - Chemical Product MSDS Name:Methyl 5-formyl-2-methyl-3-furoate 97% Material Safety Data Sheet
Synonym:5-Formyl-2-methyl-furan-3-carboxylic acid methyl este

---

Section 2 - COMPOSITION, INFORMATION ON INGREDIENTS

CAS#	Chemical Name	content	EINECS#
81661-26-9	Methyl 5-formyl-2-methyl-3-furoate	97%	unlisted

Hazard Symbols: None Listed.
Risk Phrases: None Listed.

---

Section 3 - HAZARDS IDENTIFICATION
EMERGENCY OVERVIEW
Light sensitive.
Potential Health Effects
Eye:
May cause eye irritation.
Skin:
May cause skin irritation. May be harmful if absorbed through the skin.
Ingestion:
May cause irritation of the digestive tract. May be harmful if swallowed.
Inhalation:
May cause respiratory tract irritation. May be harmful if inhaled.
Chronic:
Not available.

---

Section 4 - FIRST AID MEASURES
Eyes: Flush eyes with plenty of water for at least 15 minutes, occasionally lifting the upper and lower eyelids. Get medical aid.
Skin:
Get medical aid. Flush skin with plenty of water for at least 15 minutes while removing contaminated clothing and shoes.
Ingestion:
Get medical aid. Wash mouth out with water.
Inhalation:
Remove from exposure and move to fresh air immediately.
Notes to Physician:
Treat symptomatically and supportively.

---

Section 5 - FIRE FIGHTING MEASURES
General Information:
As in any fire, wear a self-contained breathing apparatus in pressure-demand, MSHA/NIOSH (approved or equivalent), and full protective gear.
Extinguishing Media:
Use water spray, dry chemical, carbon dioxide, or chemical foam.

---

Section 6 - ACCIDENTAL RELEASE MEASURES
General Information: Use proper personal protective equipment as indicated in Section 8.
Spills/Leaks:
Vacuum or sweep up material and place into a suitable disposal container.

---

Section 7 - HANDLING and STORAGE
Handling:
Avoid breathing dust, vapor, mist, or gas. Avoid contact with skin and eyes.
Storage:
Store in a cool, dry place. Do not store in direct sunlight. Store in a tightly closed container. Store under nitrogen.

---

Section 8 - EXPOSURE CONTROLS, PERSONAL PROTECTION
Engineering Controls:
Use adequate ventilation to keep airborne concentrations low.
Exposure Limits CAS# 81661-26-9: Personal Protective Equipment Eyes: Not available.
Skin:
Wear appropriate protective gloves to prevent skin exposure.
Clothing:
Wear appropriate protective clothing to prevent skin exposure.
Respirators:
Follow the OSHA respirator regulations found in 29 CFR 1910.134 or European Standard EN 149. Use a NIOSH/MSHA or European Standard EN 149 approved respirator if exposure limits are exceeded or if irritation or other symptoms are experienced.

---

Section 9 - PHYSICAL AND CHEMICAL PROPERTIES

Physical State: Solid
Color: yellow
Odor: Not available.
pH: Not available.
Vapor Pressure: Not available.
Viscosity: Not available.
Boiling Point: Not available.
Freezing/Melting Point: 82.5 - 83.5 deg C
Autoignition Temperature: Not available.
Flash Point: Not available.
Explosion Limits, lower: Not available.
Explosion Limits, upper: Not available.
Decomposition Temperature:
Solubility in water:
Specific Gravity/Density:
Molecular Formula: C8H8O4
Molecular Weight: 168.15

---

Section 10 - STABILITY AND REACTIVITY
Chemical Stability:
Not available.
Conditions to Avoid:
Incompatible materials, light.
Incompatibilities with Other Materials:
Oxidizing agents.
Hazardous Decomposition Products:
Carbon monoxide, carbon dioxide.
Hazardous Polymerization: Has not been reported

---

Section 11 - TOXICOLOGICAL INFORMATION
RTECS#:
CAS# 81661-26-9 unlisted.
LD50/LC50:
Not available.
Carcinogenicity:
Methyl 5-formyl-2-methyl-3-furoate - Not listed by ACGIH, IARC, or NTP.

---

Section 12 - ECOLOGICAL INFORMATION

---

Section 13 - DISPOSAL CONSIDERATIONS
Dispose of in a manner consistent with federal, state, and local regulations.

---

Section 14 - TRANSPORT INFORMATION

IATA
No information available.
IMO
No information available.
RID/ADR
No information available.

---

Section 15 - REGULATORY INFORMATION

European/International Regulations
European Labeling in Accordance with EC Directives
Hazard Symbols: Not available.
Risk Phrases:
Safety Phrases:
S 24/25 Avoid contact with skin and eyes.
WGK (Water Danger/Protection)
CAS# 81661-26-9: No information available.
Canada
None of the chemicals in this product are listed on the DSL/NDSL list.
CAS# 81661-26-9 is not listed on Canada's Ingredient Disclosure List.
US FEDERAL
TSCA
CAS# 81661-26-9 is not listed on the TSCA inventory.
It is for research and development use only.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  5-甲酰基-2-甲基-3-糠酸甲酯 在 羟胺 作用下， 以 甲醇 、 水 为溶剂， 反应 3.0h， 生成 methyl 5-((hydroxyimino)methyl)-2-methylfuran-3-carboxylate
  参考文献：
  名称：

  [EN] ISOXAZOLINE DERIVATIVES FOR CONTROLLING INVERTEBRATE PESTS
  [FR] DÉRIVÉES D'ISOXAZOLINE POUR LA LUTTE CONTRE DES ANIMAUX NUISIBLES INVERTÉBRÉS

  摘要：

  这项发明涉及公式（I）的新异氧杂环烷化合物，其中变量的含义如索赔中所示；以自由形式和盐形式存在；并且可选地包括其对映体和几何异构体。公式（I）的化合物在控制寄生虫，特别是寄生在和寄生在温血动物身上的外寄生虫方面是有用的。

  公开号：

  WO2012107533A1
• 作为产物：
  描述：

  2-甲基-3-糠酸甲酯 在 三氯氧磷 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 反应 3.0h， 以83%的产率得到5-甲酰基-2-甲基-3-糠酸甲酯
  参考文献：
  名称：

  WO2021007477A5

  摘要：

  公开号：

  WO2021007477A5

文献信息

• [EN] THIADIAZOLEDIOXIDES AND THIADIAZOLEOXIDES AS CXC- AND CC-CHEMOKINE RECEPTOR LIGANDS<br/>[FR] THIADIAZOLEDIOXYDES ET THIADIAZOLEOXIDES CONVENANT COMME LIGANDS DES RECEPTEURS DES CXC- ET CC-CHIMIOKINES
  申请人：PHARMACOPEIA INC

  公开号：WO2004033440A1

  公开（公告）日：2004-04-22

  Disclosed are novel compounds of the formula (IA) and the pharmaceutically acceptable salts and solvates thereof. Examples of groups comprising Substituent A include heteroaryl, aryl, heterocycloalkyl, cycloalkyl, aryl, alkynyl, alkenyl, aminoalkyl, alkyl or amino. Examples of groups comprising Substituent B include aryl and heteroaryl. Also disclosed is a method of treating a chemokine mediated diseases, such as, cancer, angiogenisis, angiogenic ocular diseases, pulmonary diseases, multiple sclerosis, rheumatoid arthritis, osteoarthritis, stroke and cardiac reperfusion injury, acute pain, acute and chronic inflammatory pain, and neuropathic pain using a compound of formula (IA).

  披露了公式（IA）的新颖化合物以及其中医药可接受的盐和溶剂化物。包含取代基A的基团示例包括杂芳基、芳基、杂环烷基、环烷基、芳基、炔基、烯基、氨基烷基、烷基或氨基。包含取代基B的基团示例包括芳基和杂芳基。还披露了一种治疗趋化因子介导的疾病的方法，例如，癌症、血管生成、血管生成性眼病、肺病、多发性硬化症、类风湿性关节炎、骨关节炎、中风和心脏再灌注损伤、急性疼痛、急性和慢性炎症性疼痛，以及使用公式（IA）的化合物的神经性疼痛。
• [EN] ISOTHIAZOLE DIOXIDES AS CXC- AND CC- CHEMOKINE RECEPTOR LIGANDS<br/>[FR] DIOXYDES D'ISOTHIAZOLE EN TANT QUE LIGANDS DU RECEPTEUR DE LA CHIMIOKINE CXC ET CC
  申请人：SCHERING CORP

  公开号：WO2005068460A1

  公开（公告）日：2005-07-28

  Disclosed are novel compounds of the formula (IA): and the pharmaceutically acceptable salts and solvates thereof. D and E are different groups wherein one is N and the other is CR50. Examples of groups comprising Substituent A include heteroaryl, aryl, heterocycloalkyl, cycloalkyl, aryl, alkynyl, alkenyl, aminoalkyl, alkyl or amino. Examples of groups comprising Substituent B include aryl and heteroaryl. Also disclosed is a method of treating a chemokine mediated diseases, such as, cancer, angiogenisis, angiogenic ocular diseases, pulmonary diseases, multiple sclerosis, rheumatoid arthritis, osteoarthritis, stroke and cardiac reperfusion injury, pain (e.g., acute pain, acute and chronic inflammatory pain, and neuropathic pain) using a compound of formula IA.

  公开了公式(IA)的新化合物：以及它们的药物可接受的盐和溶剂化物。D和E是不同的基团，其中一个是N，另一个是CR50。包含取代基A的基团示例包括杂芳基、芳基、杂环烷基、环烷基、芳基、炔基、烯基、氨基烷基、烷基或氨基。包含取代基B的基团示例包括芳基和杂芳基。还公开了一种治疗趋化因子介导的疾病的方法，例如，癌症、血管生成、血管生成性眼病、肺病、多发性硬化症、类风湿性关节炎、骨关节炎、中风和心肌再灌注损伤，疼痛(例如，急性疼痛、急性和慢性炎症性疼痛、神经性疼痛)使用公式IA的化合物。
• [EN] DERIVATIVES OF 1-PHENYL-2-PYRIDINYL ALKYL ALCOHOLS AS PHOSPHODIESTERASE INHIBITORS<br/>[FR] DÉRIVÉS D'ALCOOLS 1-PHÉNYL-2-PYRIDINYL ALKYLIQUES UTILISÉS EN TANT QU'INHIBITEURS DE PHOSPHODIESTÉRASE
  申请人：CHIESI FARMA SPA

  公开号：WO2012168226A1

  公开（公告）日：2012-12-13

  The invention relates to inhibitors of the phosphodiesterase 4 (PDE4) enzyme. More particularly, the invention relates to compounds that are derivatives of 1-phenyl-2-pyridinyl alkyl alcohols of formula (I), methods of preparing such compounds, compositions containing them and therapeutic use thereof.

  这项发明涉及磷酸二酯酶4（PDE4）的抑制剂。更具体地，该发明涉及公式（I）的1-苯基-2-吡啶基烷基醇衍生物化合物，制备这类化合物的方法，含有这些化合物的组合物以及它们的治疗用途。
• [EN] 3,4-DI-SUBSTITUTED CYCLOBUTENE-1, 2-DIONES AS CXC-CHEMOKINE RECEPTOR LIGANDS<br/>[FR] CYCLOBUTENE-1, 2-DIONES 3,4-DI-SUBSTITUES UTILISES COMME LIGANDS DU RECEPTEUR DE CHIMIOKINE CXC
  申请人：SCHERING CORP

  公开号：WO2004011418A1

  公开（公告）日：2004-02-05

  Disclosed are novel compounds of the formula (I)or a pharmaceutically acceptable salt or solvate thereof. Also disclosed is the treatment of chemokine-mediated diseases using compounds of the formula (II)

  揭示了公式（I）的新化合物或其药用可接受的盐或溶剂。还披露了使用公式（II）的化合物治疗趋化因子介导的疾病。
• Bisphenols from Furfurals by Organocatalysis and Gold Catalysis
  作者：A. Stephen Hashmi、J. Teles、Michael Wölfle、Wolfgang Frey

  DOI：10.1055/s-2007-982569

  日期：2007.7

  Four different benzoins were formed from furfurals by organocatalysis with heterocyclic carbenes, reduced to the diols and converted into propargyl ethers. The gold-catalyzed cyclization -exclusively gave bisphenols of the bisdihydroisobenzofuran type.

  通过与杂环卡宾的有机催化，糠醛形成四种不同的安息香，还原为二醇并转化为炔丙基醚。金催化的环化反应仅产生双二氢异苯并呋喃型双酚。